Zynerba Pharmaceuticals, Inc.
NASDAQ:ZYNE
1.3 (USD) • At close October 10, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0.086 | 0.007 | 0.007 | 0.279 | 0.81 | 0.944 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | 0.086 | 0.007 | 0.007 | 0.279 | 0.81 | 0.944 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 21.1 | 21.424 | 35.655 | 20.384 | 27.245 | 22.806 | 16.785 | 7.446 | 2.401 | 1.134 |
| General & Administrative Expenses
| 14.152 | 15.346 | 16.408 | 13.936 | 13.239 | 10.017 | 6.43 | 5.364 | 4.076 | 0.444 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 14.152 | 15.346 | 16.408 | 13.936 | 13.239 | 10.017 | 6.43 | 5.364 | 4.076 | 0.444 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 35.252 | 36.77 | 52.063 | 34.32 | 40.484 | 32.823 | 23.215 | 12.81 | 6.478 | 1.578 |
| Operating Income
| -35.252 | -36.77 | -52.063 | -34.32 | -40.398 | -32.823 | -23.208 | -12.531 | -5.668 | -0.634 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -469.742 | -4,527.312 | -3,201.052 | -44.931 | -6.997 | -0.672 |
| Total Other Income Expenses Net
| 0.216 | -0.539 | 0.726 | 1.376 | -0.475 | 0.291 | -0.289 | 0.007 | -0.002 | -0.002 |
| Income Before Tax
| -35.036 | -37.309 | -51.337 | -32.944 | -39.911 | -32.012 | -23.416 | -12.524 | -5.67 | -0.637 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -464.083 | -4,415.49 | -3,229.8 | -44.904 | -6.999 | -0.675 |
| Income Tax Expense
| -0.216 | 0.291 | -0.933 | -1.51 | 0.487 | -0.028 | -0.028 | 0.028 | 0 | 0 |
| Net Income
| -34.82 | -37.601 | -50.404 | -31.433 | -39.911 | -32.012 | -23.389 | -12.551 | -5.67 | -0.637 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -464.083 | -4,415.49 | -3,226.001 | -45.003 | -6.999 | -0.675 |
| EPS
| -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| EPS Diluted
| -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| EBITDA
| -34.62 | -36.211 | -52.544 | -34.174 | -39.923 | -33.114 | -22.919 | -12.505 | -5.641 | -0.585 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -464.223 | -4,567.47 | -3,161.239 | -44.837 | -6.964 | -0.62 |